Post-Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System.
Saved in:
| Title: | Post-Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System. |
|---|---|
| Authors: | Tran TS; Hanoi Medical University, Hanoi, Vietnam.; National Hospital of Dermatology and Venereology, Hanoi, Vietnam.; Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA., Le DV; Hanoi Medical University, Hanoi, Vietnam.; Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA., Jacobs JC; Bassett Medical Center, Cooperstown, New York, USA., Nguyen TM; National Hospital of Dermatology and Venereology, Hanoi, Vietnam.; Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA., Wetter DA; Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA., Nguyen GH; Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA. |
| Source: | International journal of dermatology [Int J Dermatol] 2026 Apr; Vol. 65 (4), pp. 825-827. Date of Electronic Publication: 2025 Sep 24. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Blackwell Science Country of Publication: England NLM ID: 0243704 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-4632 (Electronic) Linking ISSN: 00119059 NLM ISO Abbreviation: Int J Dermatol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
| ISSN: | 1365-4632 |
|---|---|
| DOI: | 10.1111/ijd.70082 |
